|1.||Ashton, J C: 2 articles (05/2014 - 02/2012)|
|2.||Harrison, James E: 2 articles (12/2005 - 04/2005)|
|3.||Whiteside, Garth T: 2 articles (12/2005 - 04/2005)|
|4.||Gottshall, Susan L: 2 articles (12/2005 - 04/2005)|
|5.||Pearson, Michelle S: 2 articles (12/2005 - 04/2005)|
|6.||Boulet, Jamie M: 2 articles (12/2005 - 04/2005)|
|7.||Valenzano, Kenneth J: 2 articles (12/2005 - 04/2005)|
|8.||Chaffer, Suzanne M: 2 articles (12/2005 - 04/2005)|
|9.||Turchin, Paul I: 2 articles (12/2005 - 04/2005)|
|10.||Mark, Lilly: 2 articles (12/2005 - 04/2005)|
04/01/2005 - "GW405833, a selective CB2 agonist, was recently reported to partially reverse the inflammation and hyperalgesia in a rat model of acute inflammation. "
02/17/2012 - "After confirming the efficacy of a systemically delivered CB2-selective agonist, GW405833, we tested this hypothesis by administering the CB2 agonists GW405833 and JWH-133, via intrathecal cannulation, to the lumbar spinal cord of rats that had undergone chronic constriction injury to induce mechanical allodynia. "
02/17/2012 - "We found that although the non-selective CB1/CB2 cannabinoid receptor agonist WIN55,212-2 reversed mechanical allodynia in both ipsilateral and contralateral hind paws, neither GW405833 nor JWH-133 reversed mechanical allodynia. "
|2.||Brain Hypoxia-Ischemia (Hypoxia Ischemia, Brain)
05/21/2014 - "As it has been shown that apparent protection soon after injury is not necessarily correlated with improved outcome after several weeks, we tested the CB2 selective agonist GW405833 in a model of cerebral hypoxia-ischemia, and assessed histological and behavioral outcomes 15 days after injury. "
12/28/2005 - "GW405833 elicited robust antihyperalgesic effects in mouse models of inflammatory (Freund's complete adjuvant) and neuropathic (Seltzer) pain. "
04/01/2005 - "In addition, GW405833 (up to 30 mg/kg) elicits potent and efficacious antihyperalgesic effects in rodent models of neuropathic, incisional and chronic inflammatory pain, the first description of this compound in these models. "
11/01/2010 - "In the pain studies, intra-articular injection of GW405833 into OA knees augmented hindlimb incapacitance, but had no effect on pain behaviour in saline-injected control joints. "
11/01/2010 - "Paradoxical effects of the cannabinoid CB2 receptor agonist GW405833 on rat osteoarthritic knee joint pain."
09/01/2009 - "Cannabinoid-2 (CB(2)) receptor-selective agonists have shown anti-nociceptive activity in models of neuropathic and inflammatory pain, and the two agonists most widely used, (+/-)AM1241 [(2-iodo-5-nitrophenyl)-[1-(1-methylpiperidin-2-ylmethyl)-1H-indol-3-yl-methanone] and L768242 [(2,3-dichloro-phenyl)-[5-methoxy-2-methyl-3-(2-morpholin-4-yl-ethyl)-indol-1-yl]-methanone] (GW405833), have been suggested to be protean agonists. "
06/01/2009 - "In contrast in CCI animals the cannabinoid CB2-selective agonist GW405833 (2,3-dichloro-phenyl)-[5-methoxy-2-methyl-3-(2-morpholin-4-yl-ethyl)-indol-1-yl]-methanone) (30 mg/kg) significantly attenuated immobility (CCI+vehicle 191+/-7s, GW405833 145+/-14s; P<0.01) and mechanical hypersensitivity (CCI+vehicle 15+/-1g, CCI+GW405833 24+/-1g; P<0.001). "
04/01/2002 - "The CB2 agonist, 1-(2,3-Dichlorobenzoyl)-5-methoxy-2-methyl-(2-(morpholin-4-yl)ethyl)-1H-indole (GW405833) inhibited the hypersensitivity and was anti-inflammatory in vivo. "
|2.||CB2 Cannabinoid Receptor
|3.||Cannabinoid Receptors (Cannabinoid Receptor)